PE20231681A1 - Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usos - Google Patents

Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usos

Info

Publication number
PE20231681A1
PE20231681A1 PE2023002389A PE2023002389A PE20231681A1 PE 20231681 A1 PE20231681 A1 PE 20231681A1 PE 2023002389 A PE2023002389 A PE 2023002389A PE 2023002389 A PE2023002389 A PE 2023002389A PE 20231681 A1 PE20231681 A1 PE 20231681A1
Authority
PE
Peru
Prior art keywords
tl1a
compositions
ligands
antibodies against
humanized antibodies
Prior art date
Application number
PE2023002389A
Other languages
English (en)
Spanish (es)
Inventor
Allison Luo
Lauren Otsuki
Mark Manning
Robert Payne
Olivier Laurent
Janine Bilsborough
Bradley Henkle
Stephan R Targan
Original Assignee
Prometheus Biosciences Inc
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometheus Biosciences Inc, Cedars Sinai Medical Center filed Critical Prometheus Biosciences Inc
Publication of PE20231681A1 publication Critical patent/PE20231681A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PE2023002389A 2021-02-18 2022-02-17 Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usos PE20231681A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163150825P 2021-02-18 2021-02-18
US202163180892P 2021-04-28 2021-04-28
US202163226037P 2021-07-27 2021-07-27
US202163285781P 2021-12-03 2021-12-03
PCT/US2022/016841 WO2022178159A1 (en) 2021-02-18 2022-02-17 Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof

Publications (1)

Publication Number Publication Date
PE20231681A1 true PE20231681A1 (es) 2023-10-19

Family

ID=82931032

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023002389A PE20231681A1 (es) 2021-02-18 2022-02-17 Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usos

Country Status (19)

Country Link
US (1) US20240309104A1 (cg-RX-API-DMAC7.html)
EP (1) EP4294444A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024506940A (cg-RX-API-DMAC7.html)
KR (1) KR20230157973A (cg-RX-API-DMAC7.html)
AU (1) AU2022223420A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023016672A2 (cg-RX-API-DMAC7.html)
CA (1) CA3207817A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023002424A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023011969A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230436A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000162A (cg-RX-API-DMAC7.html)
EC (1) ECSP23070237A (cg-RX-API-DMAC7.html)
GE (2) GEAP202416596A (cg-RX-API-DMAC7.html)
IL (1) IL305312A (cg-RX-API-DMAC7.html)
JO (1) JOP20230185A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023009622A (cg-RX-API-DMAC7.html)
PE (1) PE20231681A1 (cg-RX-API-DMAC7.html)
TW (1) TW202246322A (cg-RX-API-DMAC7.html)
WO (1) WO2022178159A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
EP3969621A4 (en) 2019-05-14 2023-01-25 Prometheus Biosciences, Inc. TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES
TW202600603A (zh) 2019-10-24 2026-01-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a (tl1a)之人類化抗體及其用途
US20260216326A1 (en) * 2022-12-22 2026-07-30 Prometheus Biosciences, Inc. Methods of treating inflammatory diseases with combination of tl1a inhibitors and s1pr inhibitors
EP4665767A2 (en) * 2023-02-17 2025-12-24 Prometheus Biosciences, Inc. Anti-tl1a antibody compositions and methods of treatment in the bile duct
IL325993A (en) 2023-08-11 2026-03-01 Paragon Therapeutics Inc TL1A binding proteins and methods of use
US12473370B2 (en) 2023-10-03 2025-11-18 Absci Corporation TL1A associated antibody compositions and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3375B1 (ar) * 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
CN105814081B (zh) * 2013-11-13 2021-02-02 辉瑞大药厂 肿瘤坏死因子样配体1a特异性抗体及其组合物和用途
US10968279B2 (en) * 2016-05-09 2021-04-06 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
MY191324A (en) * 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
CN119735681A (zh) * 2018-04-25 2025-04-01 普罗米修斯生物科学公司 优化的抗tl1a抗体
TW202600603A (zh) * 2019-10-24 2026-01-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a (tl1a)之人類化抗體及其用途

Also Published As

Publication number Publication date
BR112023016672A2 (pt) 2023-11-21
AU2022223420A1 (en) 2023-09-21
WO2022178159A1 (en) 2022-08-25
CR20230436A (es) 2023-11-01
CA3207817A1 (en) 2022-08-25
TW202246322A (zh) 2022-12-01
IL305312A (en) 2023-10-01
EP4294444A4 (en) 2025-04-16
JP2024506940A (ja) 2024-02-15
CL2023002424A1 (es) 2024-01-05
JOP20230185A1 (ar) 2023-08-09
KR20230157973A (ko) 2023-11-17
DOP2023000162A (es) 2023-10-15
EP4294444A1 (en) 2023-12-27
GEAP202416596A (en) 2024-10-28
MX2023009622A (es) 2023-08-28
US20240309104A1 (en) 2024-09-19
GEAP202316354A (en) 2023-12-25
ECSP23070237A (es) 2023-10-31
CO2023011969A2 (es) 2023-09-29

Similar Documents

Publication Publication Date Title
CL2024002330A1 (es) Anticuerpo que se une al ligando 1a similar a factor de necrosis tumoral (tl1a).
CO2023011969A2 (es) Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usos
CN104144948B (zh) 用于治疗的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig骨架
ES2818184T3 (es) Anticuerpo anti-Notch 4 humano
EA201100779A1 (ru) Композиции антител к cxcr1 и способы их применения
AR080794A1 (es) Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
PE20181336A1 (es) Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
RU2018140960A (ru) Композиции, содержащие комбинированный состав на основе антител к pd-l1 и ctla-4
AR083785A1 (es) Anticuerpos humanos contra el ligando 1a de tipo tnf (factor de necrosis tumoral) humano (tl1a)
EP3580230A1 (en) Immune-cell targeted bispecific chimeric proteins and uses thereof
EA033387B1 (ru) СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2
AR079903A1 (es) Formulacion de anticuerpo y regimenes terapeuticos. envase farmaceutico. kit.
JP2016525139A5 (cg-RX-API-DMAC7.html)
JP2016520520A5 (cg-RX-API-DMAC7.html)
ES2923677T3 (es) Novedosos anticuerpos anti-GPVI humanos y usos de los mismos
CO6140062A2 (es) Anticuerpos anti-trop-2 humanizados y quiméricos que median citotoxicidad de celulas cancerosas
PE20142422A1 (es) Anticuerpos biespecificos contra tweak humana e il 17 humana y usos de los mismos
PE20220487A1 (es) Anticuerpos anti-ms4a4a y metodos de uso de los mismos
Szabó et al. Antitumor activity of DLX1008, an anti-VEGFA antibody fragment with low picomolar affinity, in human glioma models
EA202190102A1 (ru) Коньюгаты антител к тканевым факторам с лекарственным средством и их применение в лечении рака
PE20231082A1 (es) Muteinas de il-10 y proteinas de fusion de las mismas referencia cruzada a solicitudes relacionadas
PE20251075A1 (es) Anticuerpos que se unen a la pad4 humana y usos de los mismos
AR124063A1 (es) Anticuerpo biespecífico anti-tspan8 / anti-cd3 y anticuerpo anti-tspan8
JP2024513244A5 (cg-RX-API-DMAC7.html)